Anixa Biosciences, Inc. (ANIX) Stock

Anixa Biosciences, Inc. (ANIX) is a Healthcare stock trading at $3.71 (as of 2026-08-21), with a market capitalization of $126.06M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Anixa Biosciences, Inc. is a biotechnology company developing therapies, vaccine candidates, and related immunotherapy approaches for oncology and infectious diseases. Its pipeline includes CAR-T technologies, antiviral drug candidates for COVID-19, and vaccines aimed at triple-negative breast cancer and ovarian cancer.

Understand Anixa Biosciences, Inc.: how it makes money

Anixa Biosciences develops therapies and vaccines for oncology and infectious diseases, including CAR-T technology for ovarian cancer and anti-viral drug candidates for COVID-19. The provided facts describe its R&D programs but do not specify how it currently generates revenue.

Because the company is described as developing therapies and vaccines, its profit model is tied to the progress and outcomes of its oncology and infectious disease programs, rather than a clearly defined, reportable product revenue stream in the provided data.

Business quality (Weak): Limited dataset coverage: no reportable segments, no operating KPIs, and no clear revenue model details are provided. The only quantified profitability datapoint shown is a highly negative operating margin for the latest period.

Bull case

  • Multiple focused development programs: The company is developing therapeutics programs (including chimeric endocrine receptor T-cell technology and a CAR-T approach for ovarian cancer) and anti-viral drug candidates for COVID-19 (targeting certain viral protein functions).
  • Clear unmet-need focus areas: The described therapeutic and vaccine efforts focus on critical unmet needs in oncology and infectious diseases.

Bear case

  • Profitability is currently weak based on provided metrics: For the period 2024-04-30, the operating margin shown is -1651.0, while gross margin is not provided.
  • Uncertainty due to incomplete operational disclosure in the dataset: No reportable segments or operating KPIs are provided, and the vaccine program description is truncated in the available facts, which limits visibility into near-term execution and business model.
Valuation — source: SEC EDGAR (first-party)
Price$3.71
Market Cap$126.06M
Price / Book9.53
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$210000.00
Net Margin-5978.1%
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)21.9%
FCF Growth (YoY)18.1%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($4.55M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAmit Kumar
Employees5
CountryUS
IPO Date1983-10-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Spruce Biosciences, Inc. (SPRB)
  • TuHURA Biosciences, Inc. (HURA)
  • Genelux Corporation (GNLX)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • Cumberland Pharmaceuticals Inc. (CPIX)
  • Coya Therapeutics, Inc. (COYA)
  • Rafael Holdings, Inc. (RFL)
ANIX earnings history · ANIX institutional & insider holders · ANIX KPIs & operating metrics · ANIX financials · ANIX investor presentations & press releases · ANIX SEC filings · ANIX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.